MTOR and hepatocellular carcinoma: In this study, we investigated the sensitivity of the EpCAM+ HCC cell line Huh7 and the CD90+ HCC related cell line SK-HEP1 as well as EpCAM+ primary patient-derived HCC cells towards the dual treatment with AKT and mTOR inhibitors (MK2206 and RAD001) in vitro and in an orthotopic xenotransplantation mouse model in vivo.